[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dietary-sodium-intake\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dietary-sodium-intake":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100574818",false,"NCT06764225","Effects of Low-Sodium Salt on Death, HF Hospitalization\u002F Emergency Department Visits and Quality of Life in HF Patients","Effects of Low-Sodium Substitute Salt on Death, Heart Failure Hospitalization, Heart Failure Emergency Department Visits, and Quality of Life in Patients With Heart Failure: A Multicenter, Double-Blind, Randomized Controlled Trial","RESCUE-HF","Inclusion Criteria:\n\n1. Aged between 18 and 75 years;\n2. Hospitalized due to heart failure in the past year;\n3. NYHA functional class II-III;\n4. Echocardiographic evidence of LVEF \\\u003C 40% within the past 6 months;\n5. Receiving guideline-directed medical therapy for heart failure;\n6. Stable heart failure status, defined as heart failure stability for more than 4 weeks, with no increase in diuretic dose within the past 4 weeks;\n7. Having a primary caregiver and frequently dining together at home;\n8. Consuming commercially processed food no more than once a week;\n9. Providing written informed consent.\n\nExclusion Criteria:\n\n1. End-stage heart failure;\n2. Hospitalization due to cardiovascular causes within the past month;\n3. Uncorrected hyponatremia (Na \\\u003C 130 mmol\u002FL);\n4. Dialysis-dependent patients, or eGFR \\\u003C 20 mL\u002Fmin\u002F1.73m²;\n5. Uncontrolled hyperglycemia, with fasting blood glucose \\> 16 mmol\u002FL;\n6. Malignant cancer patients with a life expectancy of less than 1 year;\n7. Conditions that, in the investigator's opinion, may interfere with adherence to the protocol, such as habitual reliance on takeout meals or dining at company cafeterias;\n8. Planned hospitalization during the study period;\n9. Unexplained weight loss greater than 5 kg in the past year;\n10. The subject or family members have concerns about using the salt substitute in this study, or are planning for pregnancy, pregnant, or breastfeeding;\n11. Another family member is already participating in this study;\n12. The subject or family members are participating in other interventional clinical trials.","ALL","18 Years","75 Years",{"count":20,"type":21},1301,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to investigate whether using a low-sodium substitute salt can help improve outcomes for patients with heart failure. Specifically, it will examine if the low-sodium substitute salt can reduce death rates, hospital readmissions, and emergency visits, as well as improve the quality of life for these patients.",[27,28],"Heart Failure","Dietary Sodium Intake",[30],"low-sodium substitute salt","RECRUITING","2025-05-16",{"date":34,"type":35},"2025-05-21","ACTUAL",{"date":37,"type":35},"2025-04-03",{"date":39,"type":21},"2027-04-30",{"name":41,"class":42},"Heart Health Research Center","OTHER",""]